Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0217 • ACR Convergence 2020
Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results
Rene Westhovens¹, William F. C. Rigby², Désirée van der Heijde³, Daniel W.T. Ching⁴, William Stohl⁵, Jonathan Kay⁶, Arvind Chopra⁷, Beatrix Bartok⁸, Franziska Matzkies⁸, Zhaoyu Yin⁸, Ying Guo⁹, Chantal Tasset¹⁰, John S. Sundy⁸, Angelika Jahreis⁸, Neelufar Mozaffarian¹¹, Osvaldo Daniel Messina¹², Robert Landewé¹³, Tatsuya Atsumi¹⁴ and Gerd Burmester¹⁵, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Timaru Hospital, Timaru, New Zealand, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Center for Rheumatic Diseases, Pune, India, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Gilead Sciences, Inc., Foster City, ¹⁰Galapagos NV, Mechelen, Belgium, ¹¹Ichnos Sciences, Paramus, ¹²IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, ¹³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ¹⁵Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an oral, potent, selective JAK 1 inhibitor. FINCH 3 assessed FIL efficacy and safety in methotrexate (MTX)-naïve patients (pts) with rheumatoid…
Abstract Number: 0234 • ACR Convergence 2020
Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Leonard Calabrese², Filip Van den Bosch³, Kunihiro Yamaoka⁴, Carlo Selmi⁵, Yanna Song⁶, Barbara Hendrickson⁷, Ivan Lagunes-Galindo⁸ and Iain McInnes⁹, ¹Oregon Health & Science University, Portland, OR, ²Cleveland Clinic, Cleveland, OH, ³Ghent University Hospital, Ghent, Belgium, ⁴Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁵Humanitas Research Hospital and Humanitas University, MIlan, Italy, ⁶AbbVie Inc., North Chicago,, IL, ⁷AbbVie, Inc, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA) is a selective and reversible Janus kinase (JAK) inhibitor with an approved dose of 15 mg once daily (QD) for the treatment…
Abstract Number: 0461 • ACR Convergence 2020
High-Throughput Single-Cell Analysis Reveals Unique Lung Cellular Subsets in a Murine Model of Rheumatoid Arthritis-Inflammatory Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Amy Nelson¹, Meng Niu¹, Chittibabu Guda¹, James Eudy¹, Austin Barry¹, Debra Romberger¹, Michael Duryee¹, Bryant England¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA)-associated inflammatory lung disease is an extra-articular manifestation of RA associated with increased morbidity and mortality, whose precise molecular mechanisms remain undetermined.…
Abstract Number: 0546 • ACR Convergence 2020
Stepping up for Inflammatory Arthritis (SUFIA): A Pilot Trial to Test Behavioral Economics Strategy to Increase Physical Activity in Inflammatory Arthritis
Alexis Ogdie¹, Kathleen Bush¹, Michael George¹, Mitesh Patel¹, William Nowell², Kelly Gavigan³, Jeffrey Curtis⁴ and Joshua Baker⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, New York City, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Regular physical activity may have benefits for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but patients with active disease are often reluctant…
Abstract Number: 0743 • ACR Convergence 2020
Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis
William Robinson¹, Chun Wu², Sarah Hu², Sean Connolly² and Sumanta Mukherjee², ¹Stanford University School of Medicine, Stanford, CT, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: ACPAs are sensitive, highly specific markers of RA. Current tests cannot differentiate ACPA+ RA subtypes. Fine-specificity ACPAs (FS) can distinguish between ACPA+ RA subtypes…
Abstract Number: 0760 • ACR Convergence 2020
X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis
Andrea Di Matteo¹, Kulveer Mankia¹, Jacqueline L Nam¹, Edoardo Cipolletta², Leticia Garcia-Montoya³, Laurence Duquenne¹, Emma Rowbotham⁴ and Paul Emery⁵, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi (AN), Italy, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: In individuals at-risk of RA, the identification of reliable biomarkers for the future development of clinical arthritis is of critical importance for risk-stratification and…
Abstract Number: 0777 • ACR Convergence 2020
CLEC12A Expression as a Potential Predictor of Disease Activity in Early Rheumatoid Arthritis
Myriam Vaillancourt¹, Philippe Desaulniers¹, Guillaume Paré¹, Nathalie Pagé¹, Asmaa Lachaab¹, Anthony Kerever¹, Anne-Sophie Julien¹, Nathalie Amiable¹, Martin Pelletier¹, Philippe Tessier¹, Louis Bessette², Paul Fortin³, Laetitia Michou¹ and Maria Fernandes¹, ¹Université Laval, Québec, QC, Canada, ²Laval University, Quebec, Canada, ³CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Rheumatoid arthritis (RA) develops as a result of the dysregulation of immune activating and inhibitory pathways. Several lines of evidence indicate that inhibitory receptors…
Abstract Number: 0794 • ACR Convergence 2020
Peripheral Blood T and B Lymphocyte Subsets in Arthritis in the Elderly
Aina Teniente-Serra¹, Lourdes Mateo², Agueda Prior³, Monica Guma⁴, Eva Martinez-Caceres¹ and Melania Martinez-Morillo⁵, ¹Department of Immunology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ²Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, ³Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain
Background/Purpose: Multiple lymphocyte subsets like T and B cells have been connected to joint infiltration and inflammation in rheumatoid arthritis (RA). Identification of leucocyte subsets…
Abstract Number: 0810 • ACR Convergence 2020
Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data
Kieran Murray¹, Matthew Turk², Yousef Alammari², Francis Young³, Phil Gallagher⁴, Tajvur Saber⁵, Sinead Maguire⁶, Finbar O'Shea⁶, Ursula Fearon⁷ and Douglas Veale⁸, ¹Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin 4, Ireland, ³Saint Vincent's University Hospital, Dublin 4, ⁴St Vincents University Hospital, UCD, Dublin, Ireland, ⁵Peshawar Rheumatology Clinic, Dabgari Garden, Northern Areas, Pakistan, ⁶St James' Hospital, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁸EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Biologic therapies are widely used and greatly improve outcomes in RA and PsA. Yet, our ability to predict long-term remission and persistence remains limited.…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 0971 • ACR Convergence 2020
Single-cell Profiling of Synovial Stromal Cells Reveals an Angiocrine Endothelium in Rheumatoid Arthritis
Kevin Wei¹, Ilya Korsunsky², Jennifer Marshall³, Gerald Watts⁴, Triin Major³, Zhu Zhu⁴, Yuhong Li⁵, Christopher Buckley⁶, Soumya Raychaudhuri⁷ and Michael Brenner¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁴Brigam and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, ⁶University of Birmingham, Birmingham, United Kingdom, ⁷Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Vascular endothelial cells that provide the structure for blood vessels have traditionally been perceived as passive, structural units that provide blood flow. We recently…
Abstract Number: 1008 • ACR Convergence 2020
Assessing Improved Risk Prediction of Seropositive Rheumatoid Arthritis by Environmental, Genetic, and Preclinical Plasma Metabolite Factors
Karen Costenbader¹, Jeffrey Sparks², Elizabeth Karlson³, Kazuki Yoshida⁴, Jing Cui⁵, Susan Malspeis⁶ and Lilia Bouzit⁷, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, ⁷Harvard Chan School of Public Health, Boston, MA
Background/Purpose: Recent research has advanced the understanding of associations between environmental, genetic, and metabolic factors and rheumatoid arthritis (RA), introducing potential to improve risk prediction.…
Abstract Number: 1179 • ACR Convergence 2020
Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study
Roxana Gonzalez Mazario¹, Jorge Juan Fragio Gil¹, Marta De la Rubia Navarro¹, Cristobal Pavez Perales¹, Samuel Leal Rodriguez², Jose Ivorra Cortes¹, Luis Gonzalez Puig³, Elena Grau Garcia², Elvira Vicens Bernabeu¹, F Ortiz-Sanjuan¹, Rosa Negueroles Albuixech¹, Cristina Alcañiz Escandell², Jose Eloy Oller Rodriguez¹, Inmaculada Chalmeta Verdejo¹, Isabel Martinez Cordellat¹, Carmen Najera Herranz¹, Ines Canovas Olmos¹, Antonio Cañada Martínez⁴ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain, ⁴HUP La Fe, Valencia, Spain
Background/Purpose: To assess the Cardiovascular Risk (CV) in Rheumatoid Arthritis (RA) patients using carotid ultasonography additionally to the traditional CV risk factors.Methods: A single center…
Abstract Number: 1195 • ACR Convergence 2020
MUC5B rs35705950 and Rheumatoid Arthritis Associated Interstitial Lung Disease Progression
Pierre-Antoine Juge¹, Joshua Solomon², Romain Garofoli³, Joyce S. Lee⁴, Fabienne Louis-Sidney⁵, Esther Ebstein¹, Jorge Rojas-Serrano⁶, Montserrat I. Gonzalez-Perez⁶, Mayra Mejia⁶, Ivette Buendia-Roldan⁶, Ramces Falfan-Valencia⁷, Enrique Ambrocio-Ortiz⁷, Effrosyni Manali⁸, Spyros A. Papiris⁸, Theofanis Karageorgas⁹, Dimitrios Boumpas⁹, Katarina Antoniou¹⁰, Coline H.M. van Moorsel¹¹, Joanne van Der Vis¹¹, Yaël A. de Man¹¹, Jan C. Grutters¹¹, Caroline Kannengiesser¹², Raphaël Borie¹³, Lidwine Wemeau-Stervinou¹⁴, Rene-Marc Flipo¹⁵, Hilario Nunes¹⁶, Yurdagul Uzunhan¹⁷, Dominique Valeyre¹⁸, Nathalie Saidenberg Kermanac'h¹⁹, Marie-Christophe Boissier²⁰, Christophe Richez²¹, Thierry Schaeverbeke²², Tracy J. Doyle²³, Paul Wolters²⁴, Marie-Pierre Debray²⁵, Catherine Boileau¹², Raphaël Porcher²⁶, Bruno Crestani¹³, David A. Schwartz⁴ and Philippe Dieude²⁷, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²National Jewish Health, Denver, CO, ³Hôpital Cochin, Service de Rééducation, Paris, Paris, France, ⁴Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO, ⁵Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ⁶Interstitial Lung Disease & Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, México City, México, Mexico, Mexico, ⁷HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas. Mexico City, Mexico, Mexico, Mexico, ⁸2nd Pulmonary Medicine Department, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ⁹Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ¹⁰PS Department of Respiratory Medicine & Laboratory of Molecular & Cellular Pneumonology, Faculty of Medicine, University of Crete, Crete, Greece, Heraklion, Greece, ¹¹St Antonius ILD center of excellence, St Antonius ziekenhuis, Nieuwegein, The Netherlands, Nieuwegein, Netherlands, ¹²Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹³Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ¹⁴CHRU de Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence des maladies pulmonaires rares, FHU IMMINENT, Lille, France, Lille, France, ¹⁵Lille University Hospital, Lille, France, ¹⁶Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ¹⁷Hôpital Avicennes, Service de Pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁸Hôpital Avicenne, Service de pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁹Hôpital Avicennes, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²⁰Hôpital Avicenne, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²¹Rheumatology Hospital, Pelligrin Hospital, Bordeaux University Hospital, Bordeaux, France, ²²CHU de Bordeaux, Service de Rhumatologie, Bordeaux, France, ²³Brigham and Women's Hospital, West Roxbury, MA, ²⁴University of California, San Francisco, San Francisco, CA, ²⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²⁶Centre d’Epidémiologie Clinique, AP-HP, Hôpital Hôtel-Dieu, F-75004 Paris, France, Paris, France, ²⁷Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) sharephenotypic and genotypic similarities. Recently, in a large international genetic association…
Abstract Number: 1211 • ACR Convergence 2020
Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies
Christina Charles-Schoeman¹, Jon Giles², Nancy Lane³, Ernest Choy⁴, Heidi Camp⁵, Yanna Song⁶, Samuel Anyanwu⁵ and Iain McInnes⁷, ¹University of California, Los Angeles, Los Angeles, CA, ²Columbia University, New York, NY, ³University of California, Davis, Sacramento, CA, ⁴CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago,, IL, ⁷Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to have greater selectivity for JAK1 vs JAK2, JAK3, and tyrosine kinase 2, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.